Compare CVS Health Corp (CVS) vs Invesco S&P 500 Momentum ETF (SPMO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Invesco S&P 500 Momentum ETF — how do they compare? CVS Health Corp trades at $86.25 (market cap $112.29B), while Invesco S&P 500 Momentum ETF trades at $152 (market cap $23.48B). The key difference: CVS Health Corp is far larger — about 4.8× Invesco S&P 500 Momentum ETF's market cap, and CVS Health Corp pays a 3.03% dividend while Invesco S&P 500 Momentum ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Invesco S&P 500 Momentum ETF for 54 Days on average.
| CVS | SPMO | |
|---|---|---|
Market Cap | $112.29B | $23.48B |
Volume | 7,763,676 | 1,876,152 |
Sector | Health | Broad Market / Factor |
52-Week High | $110.60 | $161.66 |
52-Week Low | $70.08 | $107.84 |
Typical Hold Time | 83 Days | 54 Days |
Enterprise Value | $174.64B | — |
Dividend Yield | 3.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.95, up 1.76% with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 26% upside. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $2.58 surpassing the $1.85 estimate. Revenue growth remains solid at $402.07 billion for 2025, though net margins compressed to 1.18%. Technical indicators show a bullish overall signal with support at $87 and resistance at $89.
The outlook remains positive given CVS's dominant market position and Medicare expansion plans, but investors face risks from reimbursement pressures and ongoing legal investigations. Earnings growth and successful execution of healthcare services integration represent the primary catalysts for continued stock appreciation.
SPMO trades at $153.00 with minimal daily movement (+0.01%). The ETF maintains a bullish technical stance with strong moving average signals, though oscillators show neutral momentum. Recent portfolio rebalancing added 54 stocks including Apple and Merck, while removing Nvidia. Institutional interest grew with Envestnet Asset Management increasing its stake by 9.5% in Q2 2026.
SPMO offers concentrated exposure to S&P 500 momentum leaders with historical outperformance. Key risks include sector concentration in technology and semiconductors, plus higher volatility than the broader market. The fund's momentum strategy faces challenges during market rotations but maintains structural advantages for long-term growth investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Invesco S&P 500 Momentum ETF
SPMO is designed to track the investment results of the S&P 500 Momentum Index. This index measures the performance of stocks in the S&P 500 that exhibit the highest momentum, or the greatest price appreciation, over the trailing 12 months, while excluding the most recent month. By investing in these high-momentum stocks, SPMO seeks to capitalize on the historical trend that stocks with strong recent performance tend to continue that performance in the near term, offering a systematic approach to factor investing within the large-cap U.S. equity market.
Read more on SPMO →
